FIASPFederal Inter-Agency Sedimentation Project (US Department of the Interior; also seen as FISP)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Release date- 22082019 - Bagsvaerd - Novo Nordisk today announced that the European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above).
Mads Krogsgaard Thomsen, executive vice president & chief science officer at Novo Nordisk, said: "We are very pleased with the decision of the European Commission to expand the indication of Fiasp, making it available within this younger population.
Lastly, Fiasp was approved as a new fast-acting mealtime insulin for the treatment of diabetes.
Fiasp is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Healthcare company Novo Nordisk revealed on Friday the receipt of approval from the US Food and Drug Administration (FDA) for Fiasp (insulin aspart injection) in 100 units/ml for the management of type 1 and type 2 diabetes.
Healthcare company Novo Nordisk Canada Inc reported on Monday the launch of Fiasp (insulin aspart) in Canada as a new treatment option for achieving optimal mealtime glucose control in diabetic patients in the country.
"With Fiasp, we've built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target," said Bruce Bode, MD FACE, president of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine.
Novo Nordisk, a Danish multinational pharmaceutical company, announced yesterday that Fiasp, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada.
M2 PHARMA-March 28, 2017-Novo Nordisk's Fiasp mealtime insulin launched in Canada